Seqens opens collaborative R&D space after an ‘epiphany’

By Maggie Lynch

- Last updated on GMT

Seqens opens collaborative R&D space after an ‘epiphany’

Related tags R&D France Collaboration Clinical research Pci pharma services

Seqens opens new center of excellence that houses R&D capabilities, onsite consulting, and space for coworking and collaboration in Porcheville, France.
seqens lab
Seqens lab

Seqens opened a 366,00sq-ft facility in Porcheville, France to serve as the company’s center of excellence. The facility, in close proximity to Paris, will provide R&D services to clinical research in the area and customers of Seqens North America, formerly known as PCI Synthesis.

The Procheville facility will be known as Seqens’Lab will offer expanded capabilities and include a coworking space for collaborative research.  

Christophe Eychenne-Baron, group R&D director at Seqens in Paris, told us that the company wanted to bring a new approach to finding ways to accelerate internal and customer projects that gathered its commercial team, R&D direction, and project management in one place.

According to the company, it is not just a shared laboratory and R&D hub but a ‘development accelerator.’

Eychenne-Baron explained, “We came to the epiphany that we could achieve our goals by gathering into one working area all the key internal function needed to deliver on-time projects.”

He added, “We intend to learn from our new practice here and look to roll out lessons learned and best practices to the rest of Seqens’ facilities around the world.”

Seqens’Lab will provide services in its ‘recognized areas of excellence’, including: organic chemistry development, reference to two laboratories in physics and solid-state chemistry and process safety, kinetic and thermodynamic simulation tools, and large batch manufacturing capabilities for preclinical and clinical studies.

Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

Related suppliers

Follow us

Products

View more

Webinars